191 related articles for article (PubMed ID: 35506699)
1. Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Chirehwa M; Winckler JL; Mao J; Draper HR; Wiesner L; Norman J; McIlleron H; Donald PR; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0226421. PubMed ID: 35506699
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.
de Kock L; Sy SK; Rosenkranz B; Diacon AH; Prescott K; Hernandez KR; Yu M; Derendorf H; Donald PR
Antimicrob Agents Chemother; 2014 Oct; 58(10):6242-50. PubMed ID: 25114132
[TBL] [Abstract][Full Text] [Related]
3. N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.
Sy SK; de Kock L; Diacon AH; Werely CJ; Xia H; Rosenkranz B; van der Merwe L; Donald PR
Antimicrob Agents Chemother; 2015 Jul; 59(7):4129-38. PubMed ID: 25963985
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
[TBL] [Abstract][Full Text] [Related]
5. Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens.
Abulfathi AA; Assawasuwannakit P; Donald PR; Diacon AH; Reuter H; Svensson EM
Eur J Clin Pharmacol; 2020 Nov; 76(11):1557-1565. PubMed ID: 32588106
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Para-Aminosalicylic Acid and Its 2 Major Metabolites: A Potential Relationship to the Development of Gastrointestinal Intolerance.
Adams KT; Donald PR; Abulfathi AA; Diacon AH; Stander MA; Reuter H
J Clin Pharmacol; 2020 Apr; 60(4):489-494. PubMed ID: 31682027
[TBL] [Abstract][Full Text] [Related]
7. Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PAS-GR) in multidrug-resistant tuberculosis.
Kibleur Y; Brochart H; Schaaf HS; Diacon AH; Donald PR
Clin Drug Investig; 2014 Apr; 34(4):269-76. PubMed ID: 24488376
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.
Zhang C; McIlleron H; Ren Y; van der Walt JS; Karlsson MO; Simonsson US; Denti P
Antivir Ther; 2012; 17(1):25-33. PubMed ID: 22267466
[TBL] [Abstract][Full Text] [Related]
9. Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
Denti P; Garcia-Prats AJ; Draper HR; Wiesner L; Winckler J; Thee S; Dooley KE; Savic RM; McIlleron HM; Schaaf HS; Hesseling AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133560
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.
Abulfathi AA; Donald PR; Adams K; Svensson EM; Diacon AH; Reuter H
Br J Clin Pharmacol; 2020 Nov; 86(11):2123-2132. PubMed ID: 32470182
[TBL] [Abstract][Full Text] [Related]
11. Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis.
van der Laan LE; Garcia-Prats AJ; McIlleron H; Abdelwahab MT; Winckler JL; Draper HR; Wiesner L; Schaaf HS; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0061123. PubMed ID: 37971239
[TBL] [Abstract][Full Text] [Related]
12. Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
Galileya LT; Wasmann RE; Chabala C; Rabie H; Lee J; Njahira Mukui I; Hesseling A; Zar H; Aarnoutse R; Turkova A; Gibb D; Cotton MF; McIlleron H; Denti P
PLoS Med; 2023 Nov; 20(11):e1004303. PubMed ID: 37988391
[TBL] [Abstract][Full Text] [Related]
13. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir.
Rabie H; Tikiso T; Lee J; Fairlie L; Strehlau R; Bobat R; Liberty A; McIlleron H; Andrieux-Meyer I; Cotton M; Lallemant M; Denti P
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071055
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic evaluation of para-aminosalicylic acid granules.
Peloquin CA; Henshaw TL; Huitt GA; Berning SE; Nitta AT; James GT
Pharmacotherapy; 1994; 14(1):40-6. PubMed ID: 8159600
[TBL] [Abstract][Full Text] [Related]
16. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
17. Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin.
Zhang C; Denti P; Decloedt EH; Ren Y; Karlsson MO; McIlleron H
Br J Clin Pharmacol; 2013 Nov; 76(5):741-51. PubMed ID: 23432610
[TBL] [Abstract][Full Text] [Related]
18. Para-aminosalicylic acid: the return of an old friend.
Donald PR; Diacon AH
Lancet Infect Dis; 2015 Sep; 15(9):1091-1099. PubMed ID: 26277036
[TBL] [Abstract][Full Text] [Related]
19. Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India.
Aruldhas BW; Hoglund RM; Ranjalkar J; Tarning J; Mathew SK; Verghese VP; Bose A; Mathew BS
Br J Clin Pharmacol; 2019 Mar; 85(3):644-654. PubMed ID: 30588647
[TBL] [Abstract][Full Text] [Related]
20. Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.
Radtke KK; Hesseling AC; Winckler JL; Draper HR; Solans BP; Thee S; Wiesner L; van der Laan LE; Fourie B; Nielsen J; Schaaf HS; Savic RM; Garcia-Prats AJ
Clin Infect Dis; 2022 Apr; 74(8):1372-1381. PubMed ID: 34286843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
